Aldose Reductase Inhibitor

Govorestat (AT-007) is an orally active brain-penetrant aldose reductase inhibitor with an IC₅₀ value of 100 pM. Govorestat has the potential for galactose-1-phosphate uridyl transferase deficiency research.

MK204 is an aldose reductase (AR) inhibitor that can be used in diabetes research.

Danshenol A, an abietane-type diterpenoid, is an aldose reductase (AR) inhibitor with an IC₅₀ of 0.1 μM. Danshenol A can protect endothelial cells from oxidative stress by directly scavenging ROS. Danshenol A has anti-inflammatory and antitumor properties. Danshenol A can be used for atherosclerosis research.

Imirestat (AL 1576) is an aldose reductase inhibitor, used for the treatment of diabetes.

Soyasaponin Ba is a soyasaponin that can be isolated from Phaseolus vulgaris, acts as an aldose reductase inhibitor (ARI). Soyasaponin Ba activates Akt/GSK3β/β-catenin signaling pathway, reduces lipid accumulation, lowers ROS generation, improves mitochondrial membrane potential, ATP levels, and morphology, and inhibits apoptosis. Soyasaponin Ba can be used for the research of lipid accumulation and secondary diabetic complications.

Exisulind is an inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac. Exisulind inhibits aldose reductase with an IC₅₀ of 367 nM in vitro and may contribute to the beneficial pharmacological effects of sulindac on type 2 diabetic complications.

Demethoxycapillarisin (6-Demethoxycapillarisin) is a natural polyphenolic compound of the benzochromone class. Demethoxycapillarisin inhibits aldose reductase (ALR2); it also downregulates PEPCK transcription, thereby inhibiting hepatic gluconeogenesis, with an IC₅₀ of 43 µM. Demethoxycapillarisin is an active component with pro-adipogenic activity in Artemisia scoparia, and it is speculated to regulate AMPK through a coumarin-related mechanism. Demethoxycapillarisin can be used in diabetes-related research.

Caficrestat (AT-001) is an orally active aldose reductase inhibitor. Caficrestat can be used in the study of diabetic cardiomyopathy.

Glyoxal (40% w/w in water) is an α-oxoaldehyde that inhibits Aldose Reductase, Glutathione Reductase, and NADPH synthase. Glyoxal (40% w/w in water) exhibits cytotoxicity, triggers oxidative stress, induces ROS accumulation, lipid peroxidation, mitochondrial membrane potential collapse, DNA damage, apoptosis, and massive production of advanced glycation end products (AGEs). Glyoxal (40% w/w in water) depletes glutathione and activates MAPK phosphorylation. It has lower toxicity as a fixative than paraformaldehyde (PFA) and serves as a precursor for the synthesis of oxalates and dietary carcinogens. Glyoxal (40% w/w in water) is suitable for research related to calcium oxalate kidney stones, diabetes, atherosclerosis, cardiovascular diseases, retinopathy, and cataracts.

Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats.

Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC₅₀ of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation.

WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis.

Alrestatin (AY-22284) is an aldose reductase inhibitor. Alrestatin reduces fructose levels in the uterine fluid of mice. Alrestatin interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin can be used in studies related to diabetes and reproductive diseases.

2,2'-Thiodiacetic acid (Thiodiglycolic acid) is a human L-xylulose reductase (XR) inhibitor with inhibition rate of 28% at 10 mM. 2,2'-Thiodiacetic acid can be used for the research of diabetes .

Cornoside is a phenolic glycoside and has inhibitory effect on rat lens aldose reductase (AR) with an IC₅₀ of 150 μM.

JSD26 is a selective and orally active SCoR2 (AKR1A1) inhibitor with an IC₅₀ of 93 nM. JSD26 has 10-fold selectivity for SCoR2 versus AKR1B1. JSD26 can be used for the study acute kidney injury (AKI).

ALR2-IN-1 is a potent and selective ALR2 inhibitor (IC₅₀=1.42 μM). ALR2-IN-1 shows antioxidant and antiglycative properties. ALR2-IN-1 can be used in diabetic complication research.

Tolrestat (Standard) is the analytical standard of Tolrestat. This product is intended for research and analytical applications. Tolrestat is a potent, orally active aldose reductase inhibitor with IC₅₀ of 35 nM.

Epalrestat (Standard) is the analytical standard of Epalrestat. This product is intended for research and analytical applications. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.

Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications.